Brokerages Set Sanofi (NASDAQ:SNY) Target Price at $57.50

Shares of Sanofi (NASDAQ:SNY) have received a consensus recommendation of “Moderate Buy” from the four brokerages that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $57.50.

A number of research analysts have issued reports on the stock. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th.

Institutional Investors Weigh In On Sanofi

Large investors have recently modified their holdings of the business. B. Riley Wealth Advisors Inc. boosted its stake in shares of Sanofi by 32.4% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 20,925 shares of the company’s stock valued at $1,122,000 after purchasing an additional 5,117 shares in the last quarter. Tidal Investments LLC acquired a new stake in Sanofi in the first quarter valued at approximately $228,000. Atria Investments Inc grew its stake in shares of Sanofi by 31.1% during the first quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock worth $4,805,000 after buying an additional 23,463 shares during the last quarter. Redwood Grove Capital LLC increased its holdings in shares of Sanofi by 9.1% during the first quarter. Redwood Grove Capital LLC now owns 261,154 shares of the company’s stock worth $12,692,000 after buying an additional 21,710 shares in the last quarter. Finally, Cetera Investment Advisers increased its holdings in shares of Sanofi by 245.4% during the first quarter. Cetera Investment Advisers now owns 178,349 shares of the company’s stock worth $8,668,000 after buying an additional 126,712 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Trading Down 0.5 %

Shares of NASDAQ:SNY opened at $48.49 on Thursday. The company has a 50-day simple moving average of $52.80 and a 200 day simple moving average of $52.13. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The company has a market capitalization of $123.06 billion, a P/E ratio of 24.74, a price-to-earnings-growth ratio of 1.23 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period last year, the firm posted $2.55 EPS. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. Sell-side analysts forecast that Sanofi will post 4.29 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.